Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdCh63 AMA1 + MVA AMA1 + AMA1-C1 + CPG 7909
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
AdCh63 AMA1 + MVA AMA1 + AMA1-C1 + CPG 7909 is a multi-component, heterologous prime-boost malaria vaccine regimen developed by the University of Oxford. The regimen targets the blood-stage of Plasmodium falciparum infection by inducing immune responses against the Apical Membrane Antigen 1 (AMA1), a protein essential for merozoite invasion of erythrocytes. It utilizes two viral vector vaccines—a chimpanzee adenovirus (AdCh63) and a modified vaccinia virus Ankara (MVA)—both engineered to express the AMA1 antigen. These are combined with a recombinant protein component, AMA1-C1, which contains AMA1 sequences from the FVO and 3D7 clones of P. falciparum. The protein is formulated with Alhydrogel and the TLR9 agonist adjuvant CPG 7909 to enhance immunogenicity. This mixed-modality approach is designed to elicit potent cellular and humoral immune responses to block malaria infection.
- Other names
- ChAd63 AMA1 + MVA AMA1 + AMA1-C1 + CPG 7909AdCh63 AMA1/MVA AMA1/AMA1-C1/Alhydrogel + CPG 7909AdCh63 AMA1 + MVA AMA1 + AMA1-C1 + CPG 7909-University of Oxford-malaria
02
Targets
TLR9 (Toll-like receptor 9)AMA1 (Apical membrane antigen 1)
Beyond the preview
Go deeper on AdCh63 AMA1 + MVA AMA1 + AMA1-C1 + CPG 7909.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdCh63 AMA1 + MVA AMA1 + AMA1-C1 + CPG 7909.